Is it time to move on to the next generation of clinical trials in older patients with cancer?

Affiliations

¹ Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals Foundation NHS Trust, Newcastle upon Tyne, UK.
² Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals Foundation NHS Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK. Electronic address: alastair.greystoke@newcastle.ac.uk.

Free article

Comment

Hannah Lowe et al. Lancet Healthy Longev. 2021 Dec.

Free article

. 2021 Dec;2(12):e774-e775.

doi: 10.1016/S2666-7568(21)00279-8.

¹ Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals Foundation NHS Trust, Newcastle upon Tyne, UK.
² Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals Foundation NHS Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK. Electronic address: alastair.greystoke@newcastle.ac.uk.

No abstract available

Conflict of interest statement

We declare no competing interests.

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Ebi N, Inoue A, Kurata T, Okamoto I, Yamaguchi M, Harada T, Seike M, Ando M, Saito AM, Kubota K, Takenoyama M, Seto T, Yamamoto N, Gemma A. Kogure Y, et al. Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. doi: 10.1016/S2666-7568(21)00255-5. Lancet Healthy Longev. 2021. PMID: 36098037 Clinical Trial.